Events

CHI 2013 Annual Meeting

Genentech, S. San Francisco

2013-CHI-AM-banner

What are your partners and colleagues doing to prepare for the implementation of the Affordable Care Act (ACA)? In the face of the largest domestic policy change since Medicare, how can the biomedical ecosystem ensure that the pipeline for innovation is not damaged?

Your peers will find out at CHI’s annual meeting. Would you like to join the conversation?

For over 20 years, CHI has been a powerful and respected voice for the industry. This year’s annual meeting will bring together leaders from different segments of the biomedical ecosystem. Let your voice be heard by your peers. Register today.


Register for the Annual Meeting and attend our Coverage & Payment Workshop for Free!

CHI-SF-210 FOR WEB USE ONLY AM3 CHI-SF-653 FOR WEB USE ONLY CHI-SF-516 FOR WEB USE ONLY

Hotel Information

SOLD OUT. Click here for alternative hotel options.

The Westin St. Francis
335 Powell St
San Francisco, CA 94102
Reservation line: 800-937-8461
Group Name: California Healthcare Institute
November 20th room rate (based on availability): $349++
November 21st room rate (based on availability): $169++

Questions? Please contact CHI’s marketing and communications coordinator, Will Zasadny (858-456-8881 or Zasadny@chi.org).

CHI 2013 Annual Meeting
November 21, 8 – 6 p.m.
Genentech, S. San Francisco Way

Agenda
Time

Agenda Item
7:30 – 8:00 a.m. Registration
8:00 – 8:30 a.m. The Many Faces of Patient Care

Over the past 20 years, good science and policy improvements have allowed for effective patient care and medical solutions. Come meet a few faces of those who faced daunting diseases, and survived.

  • Jessica Kwiatkowski, Event Planner & Executive Assistant, Thomson Reuters; Breast Cancer Survivor
  • Douglas Brooks, Senior Vice President, Justice Resource Institute, HIV Patient
  • Lester Tenney, Ph.D., Chairman, Care Packages From Home, Transcatheter Aortic valve Replacement Patient

8:30 – 8:40 a.m. Welcome Remarks

  • Steve Krognes, Senior Vice President, Regional Head, Finance and IT and Chief Financial Officer, Pharma North America, Genentech

8:45 – 9:45 a.m. Advancing Innovation & Access Under an Evolving Healthcare Landscape

As health exchanges are rolled out and Medicaid is expanded, it is critical that importance is placed on treatments that bring the best value, and not on treatments that are low cost but ineffective. Innovators, payers, regulators, and patients all play roles in advancing a sustainable healthcare system.

  • Moderator: Roy Baynes, M.D., Ph.D., Senior Vice President, Oncology Therapeutics
  • Eve Bukowski, Cancer Patient Advocate, and VP – State Government Affairs, CHI
  • Holbrook Kohrt, M.D., Ph.D., Assistant Professor of Medicine (Oncology), Stanford University Medical Center
  • David Purdie, Head, Quality of Care and Patient Access, GNE Medical Affairs, Genentech

9:45 – 10:30 a.m. Networking Break

10:30 – 11:00 a.m. 2014 Biomedical Industry Report

  • David Gollaher, Ph.D., President & CEO, CHI
  • Peter Claude, Partner, PwC

11:05 a.m. – 12:00 p.m. Coverage and Payment for Innovation

The Affordable Care Act (ACA) is accelerating many changes that the healthcare sector will have to respond to in coming years. The landscape is rapidly transforming with the advent of provider consolidation, mechanisms such as Accountable Care Organizations (ACOs) and bundled payments, and broad adoption of Health Information Technology (HIT) and clinical decision support tools. This panel will discuss what the key issues will be in ensuring that life science companies and innovators are able to align with the “value-driven” goals of health plans, providers, clinicians, and patients.

  • Moderator: Joshua Ofman, M.D., M.S.H.S., SVP, Global Value, Access and Policy, Amgen
  • Tanisha Carino, Ph.D., Executive Vice President, Avalere Health
  • Geoffrey Joyce, Ph.D., Associate Professor, Pharmaceutical Economics, University of Southern California; Director, Health Policy, Leonard D. Schaeffer Center; Research Associate, National Bureau of Economic Research; Director, AHRQ Postdoctoral Training Program
  • Dana Mead, Jr., Partner, Kleiner Perkins Caufield & Byers

12:00 – 12:10 p.m. Founder’s Award Presentation

  • Gavin S. Herbert, Founder & Chairman Emeritus, Allergan

12:10 p.m. – 1:30 p.m. Chairman’s Luncheon

The biomedical sector is a vibrant and complex ecosystem that relies heavily on sound policy and regulation to succeed. During this lunch session, biomedical leaders will reflect on the sector’s challenges and how advocacy can help drive key issues forward. Panelists will discuss:

  • The value of operating under one coalition to push key issues through in Washington D.C. and Sacramento.
  • How aligning with CHI benefits the individual organization, and the biomedical ecosystem at large.

Session 1

  • Moderator: David Gollaher, Ph.D., President & CEO, CHI
  • John Martin, Ph.D., Chairman & CEO, Gilead Sciences
  • Carl Hull, former CEO, Gen-Probe
  • Michael Mussallem, Chairman and CEO, Edwards Lifesciences

Session 2

  • Moderator: Chris Nolet, Partner, Ernst & Young
  • David Pyott, Chairman & CEO, Allergan
  • George Scangos, Ph.D., CEO, Biogen Idec

1:30 – 1:40 p.m. Break

1:40 – 2:40 p.m. FDA: Science and Policy

  • Moderator: Emily Marden, Counsel, Sidley Austin
  • Dirk Calcoen, M.D.,  Managing Partner, Boston Consulting Group
  • Bruce Cozadd, Chairman and Chief Executive Officer, Jazz Pharmaceuticals
  • Heather Mason, Senior Vice President, Abbott Diabetes Care

2:40 – 3:30 p.m. Manatt Phelps Phillips
Networking Break and Salon Interactive

  • Jerry Hill, State Senator, California’s 13th District
  • Kevin Mullin, Assembly Member, California’s 22nd District
  • Richard Costigan, Senior Director of State & Government Affairs, Manatt, Phelps & Phillips, LLP

3:30 – 4:20 p.m. Nurturing Innovation in California

Last year, life sciences companies in California developed nine of the 39 novel medicines approved by the FDA. To keep innovation moving forward in California, there must be investment into the supporting ecosystem. This panel will discuss the roles that companies, research institutes, and venture capitalists  play in fostering the growth of emerging technologies.

  • Moderator: David Martin, M.D., CEO, AvidBiotics
  • Teri Melese, Ph.D., Assistant Vice Chancellor of Industry Research Alliances, UCSD
  • Cami Samuels, Affiliated Director, Versant Ventures
  • Peter DiLaura, President & CEO, Second Genome
  • Thorsten Melcher, Ph.D., Senior Director, New Ventures & Partnerships, California Innovation Center, Johnson & Johnson

4:25 – 5:00 p.m. Shaping Tomorrow’s Policies

  • David Beier, Managing Director, Bay City Capital
  • Ginger Graham, President & CEO, Two Trees Consulting

5:00 – 5:10 p.m. Closing Remarks

  • Rick Winningham, Chairman & Chief Executive Officer, Theravance

5:10 – 6:00 p.m. Closing Reception

  • Peter Claude, Partner, PricewaterhouseCoopers

 

Register Now for CHI’s 2013 Annual Meeting and get earlybird pricing!
Register for the Annual Meeting, attend our Coverage & Payment Workshop for Free!

CHI Member Price
Commercial/Service Provider $699
Development-Stage Organizations (Revenue under $25 M) $129
Academic/Non-Profit Organizations $129
Non CHI Member
Commercial/Service Provider $899
Development-Stage Organizations (Revenue under $25 M) $199
Academic/Non-Profit Organizations $199

 

Hotel Information

SOLD OUT. Click here for alternative hotel options.

The Westin St. Francis
335 Powell St
San Francisco, CA 94102
Reservation line: 800-937-8461
Group Name: California Healthcare Institute
Room rate (based on availability): $349++

banner_hotel_boeken

NextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnailNextGen ScrollGallery thumbnail
Gavin Herbert, Founder, Allergan
Gavin Herbert, Founder, Allergan
David Beier, Managing Director, Bay City Capital
David Beier, Managing Director, Bay City Capital
Teri Melese, Ph.D., Assistant Vice Chancellor, UCSD
Teri Melese, Ph.D., Assistant Vice Chancellor, UCSD
Geoffrey Joyce, Ph.D., Associate Professor, USC
Geoffrey Joyce, Ph.D., Associate Professor, USC
Heather Mason, Senior Vice President, Abbott Diabetes Care
 Heather Mason, Senior Vice President, Abbott Diabetes Care
Carl Hull, former Chief Executive Officer, Gen-Probe
 Carl Hull, former Chief Executive Officer, Gen-Probe
Roy Baynes, M.D., Ph.D., Senior Vice President, Oncology Therapeutics
 Roy Baynes, M.D., Ph.D., Senior Vice President, Oncology Therapeutics
Lester Tenney, Ph.D., Chairman, Care Packages From Home
 Lester Tenney, Ph.D., Chairman, Care Packages From Home
Michael Mussallem, CEO, Edwards Lifescience
 Michael Mussallem, CEO, Edwards Lifescience
Cami Samuels, Affiliated Director, Versant Ventures
 Cami Samuels, Affiliated Director, Versant Ventures
Chris Nolet, Partner, Ernst & Young
 Chris Nolet, Partner, Ernst & Young
David Pyott, Chairman & Chief Executive Officer, Allergan
 David Pyott, Chairman & Chief Executive Officer, Allergan
George Scangos, Ph.D., Chief Executive Officer, Biogen Idec
 George Scangos, Ph.D., Chief Executive Officer, Biogen Idec
Ginger Graham, President & Chief Executive Officer, Two Trees Consulting
 Ginger Graham, President & Chief Executive Officer, Two Trees Consulting
Holbrook Kohrt, M.D., Ph.D., Assistant Professor of Medicine, Stanford University
 Holbrook Kohrt, M.D., Ph.D., Assistant Professor of Medicine, Stanford University
John Martin, Ph.D., Chairman & Chief Executive Officer, Gilead Sciences
 John Martin, Ph.D., Chairman & Chief Executive Officer, Gilead Sciences
Douglas Brooks, Director of Evaluation and Planning at JRI Health.© 2005 Marilyn Humphries
Douglas Brooks, Director of Evaluation and Planning at JRI Health.© 2005 Marilyn Humphries
steve-krognes-senior-vice-president-regional-head-finance-and-it-and-chief-financial-officer-pharma-north-america-genentech-jpg
steve-krognes-senior-vice-president-regional-head-finance-and-it-and-chief-financial-officer-pharma-north-america-genentech-jpg
Adam Keeney, Vice President of Transactions & Partnerships, Johnson & Johnson Innovation
Adam Keeney, Vice President of Transactions & Partnerships, Johnson & Johnson Innovation
Peter DiLaura, President & CEO, Second Genome
 Peter DiLaura, President & CEO, Second Genome
Rick Winningham, Chairman & Chief Executive Officer, Theravance
Rick Winningham, Chairman & Chief Executive Officer, Theravance
Brook Byers, Senior Partner, Kleiner Perkins Caufield & Byers
Brook Byers, Senior Partner, Kleiner Perkins Caufield & Byers
David Purdie, Head, Quality of Care & Patient Access, Genentech
David Purdie, Head, Quality of Care & Patient Access, Genentech
Dana Mead, Jr., Partner, Kleiner Perkins Caufield & Byers
Dana Mead, Jr., Partner, Kleiner Perkins Caufield & Byers
David Martin, M.D., CEO, AvidBiotics
David Martin, M.D., CEO, AvidBiotics
Dirk Calcoen, M.D., Managing Partner, Boston Consulting Group
Dirk Calcoen, M.D., Managing Partner, Boston Consulting Group
Eve Bukowski, Vice President, State Government Affairs, CHI
Eve Bukowski, Vice President, State Government Affairs, CHI
Jessica Kwiatkowski, breast cancer survivor
Jessica Kwiatkowski, breast cancer survivor
Joshua Ofman, SVP, Global Value and Access, Amgen
Joshua Ofman, SVP, Global Value and Access, Amgen
Peter Claude, Partner, PricewaterhouseCoopers
Peter Claude, Partner, PricewaterhouseCoopers

Confirmed Speakers Include:

  • Roy Baynes, M.D., Ph.D., Senior Vice President, Oncology Therapeutics
  • David Beier, Managing Director, Bay City Capital
  • Douglas Brooks, Senior Vice President, Justice Resource Institute
  • Brook Byers, General Partner, Kleiner Perkins Caufield & Byers
  • Dirk Calcoen, Partner and Managing Director, Boston Consulting Group
  • Bruce Cozadd, Chairman and Chief Executive Officer, Jazz Pharmaceuticals
  • Peter DiLaura, President & CEO, Second Genome
  • John Martin, Ph.D., Chairman & CEO, Gilead Sciences
  • Ginger Graham, President & Chief Executive Officer, Two Trees Consulting
  • Carl Hull, former Chief Executive Officer, Gen-Probe
  • Geoffrey Joyce, Ph.D., Associate Professor, Pharmaceutical Economics, University of Southern California; Director, Health Policy, Leonard D. Schaeffer Center; Research Associate, National Bureau of Economic Research; Director, AHRQ Postdoctoral Training Program
  • Adam Keeney, Vice President of Transactions & Partnerships, Johnson & Johnson Innovation
  • Holbrook Kohrt, M.D., Ph.D., Assistant Professor of Medicine (Oncology), Stanford University Medical Center
  • Emily Marden, Counsel, Sidley Austin
  • David Martin, M.D., CEO, AvidBiotics
  • Teri Melese, Ph.D., Assistant Vice Chancellor of Industry Research Alliances, UCSD
  • Michael Mussallem, Chairman & Chief Executive Officer, Edwards Lifescience
  • Chris Nolet, Partner, Ernst & Young
  • Joshua Ofman, M.D., SVP, Global Value and Access, Amgen
  • David Purdie, Head, Quality of Care and Patient Access, GNE Medical Affairs, Genentech
  • David Pyott, Chairman & Chief Executive Officer, Allergan
  • Cami Samuels, Affiliated Director, Versant Ventures
  • George Scangos, Ph.D., Chief Executive Officer, Biogen Idec.
  • Ian Spatz, Senior Advisor, Manatt, Phelps & Phillips, LLP
  • Rick Winningham, Chairman & Chief Executive Officer, Theravance